Comparative Assessment of Efficacy & Safety of Sacubitril/Valsartan Versus Ramipril in Patients With Renal Dysfunction Hospitalized With Acute Decompensated Heart Failure

Sacubitril/valsartan is an established medication for heart failure. However, data still lags in its use in heart failure patients with chronic kidney disease. Sacubitril/valsartan is manufacturer-labeled for use in patients with eGFR \< 30 ml/min/1.73 m2 at an initial dose of 24/26mg twice daily. However, to the best of our knowledge, the concept of sacubitril/valsartan or ACEi in patients with chronic kidney disease \& presenting with decompensated heart failure has not yet been explored fully.

NCT Number	NCT07023016
Lead Sponsor	National Heart Institute, Egypt Collaborators: Cairo University
Conditions	Acute Decompensated Heart Failure (ADHF), Chronic Kidney Disease (CKD)
Enrollment	515 participants
Start Date	2023-11-01
Primary Completion	2025-02-28 (estimated)
Study Completion	2025-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-13